ALK and metastatic neoplasm: Additionally, because amendments to capture additional data were made in the middle of the project (a sign of the learning curve in designing novel prospective RWE studies), the duration of treatment on prior ALK TKIs and time from metastatic disease to lorlatinib initiation was not available in approximately half of patients.